To read the full story, subscribe or sign in.

Luoxin’s PIK3α inhibitor receives trial nod in China after Novartis’ alpelisib

May 19, 2020

BEIJING – Shandong, China-based Luoxin Pharmaceuticals Group Stock Co. Ltd. said its PIK3α inhibitor, LX-086, has been approved by China’s National Medical Products Administration (NMPA) to enter clinical trials for advanced solid tumors.

BioWorld Asia Clinical Regulatory China IND NMPA

Today's news in brief

BioWorld

BioWorld briefs for July 22, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 22, 2025.

Coinfections and diversity paint the many shades of HIV cure

BioWorld

We all look different to HIV, a virus that destroys the immune system. The defensive cells record every interaction with foreign agents, infections from viruses...

Livzon’s IL-17A/F meets phase III endpoints in plaque psoriasis

BioWorld

Livzon Mabpharm Inc.’s anti-IL-17A/F monoclonal antibody, LZM-012, met the primary endpoint in a phase III trial in moderate to severe plaque psoriasis. Conducted...

Sino to acquire Lanova and pipeline for up to $950M

BioWorld Asia

Sino Biopharmaceutical Ltd. agreed to fully acquire Lanova Medicines Ltd. by buying an additional 95.09% stake in Lanova at a valuation of up to $950.92 million....